News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Asterand, Inc. Announces New Cell Lines To Advance Prostate Cancer Research


10/19/2005 5:10:01 PM

DETROIT, Feb. 17 /PRNewswire/ -- Cancer researchers are being offered six new cell lines to speed the search for a cure for prostate cancer. The new research material is being made available today by Asterand, the Detroit based human tissue bank.

The new cell lines are the result of a two-year collaboration between Asterand and Onyvax Ltd., a UK company that is developing vaccines for prostate and other cancers. Researchers at Wayne State University and the Karmanos Cancer Institute -- both in Detroit -- also participated in the development and characterization of the new lines.

"These new lines are important because they effectively double the material available to researchers," says Dr. James Eliason, head of Research for Asterand. "Until now there have been only three prostate cancer lines commonly available for study. Each cell line represents a single patient and every patient is different so it is useful to examine different lines. Now we are offering three lines representing the disease plus three cell lines representing normal prostate tissue."

Prostate Cancer is a major disease of older men throughout the world. In the USA it affects 9 million men and results in a death every 13 minutes. It is second only to lung cancer in causing death in men and affects African American men in particular. The new cell lines will be used to establish a better understanding of the causes of prostate cancer as well as the specific screening of potential new drugs and development of therapeutics.

Asterand provides research material to the world's leading drug discovery companies. Clients include large pharmaceutical companies, specialized biotechnology companies as well as individual researchers at academic institutions.

"This is just another part of a massive resource that we are building for the investigation into the genetic basis of human diseases," said Asterand CEO Randal Charlton. "We provide a wide range of research material backed by detailed clinical data for research into all forms of cancer as well as other important diseases such as diabetes, osteoarthritis, cardiovascular disease and various neurological diseases."

Details of the new cell lines will be presented to scientists at the American Association of Cancer Research at its annual meeting in March at Orlando, Florida. Researchers can also obtain detailed information via the company web site, http://www.asterand.com/ .

Asterand

CONTACT: James Eliason, Ph.D., +1-313-966-7858, or Randal Charlton,+1-313-874-7174, both of Asterand


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES